title: Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon.
abstract: BACKGROUND
  Currently, there is still a lack of an optimal treatment for no-reflow phenomenon (NR). The aim of this simple meta-analysis was to evaluate the efficacy and safety of intracoronary (IC) administration of tirofiban compared with other conventional drugs during percutaneous coronary intervention (PCI) for NR.
  
  
  METHODS
  Systematic literature search was done from PubMed, EMBASE, Google Scholar, EBSCO, Springer and CNKI databases without language or time limitation. Randomized controlled trials were enrolled for analyzing if they investigated the treatment of IC administration of tirofiban versus other conventional drugs for NR.
  
  
  RESULTS
  Ten studies with 702 patients were included. Significantly, the treatment of tirofiban was more effective in improving the thrombolysis in myocardial infarction (TIMI) flow (OR 0.24, 95% CI 0.15-0.37, P < 0.00001) and reducing major adverse cardiovascular events (MACE) (OR 0.09, 95% CI 0.05-0.18, P < 0.00001). There was a trend to increase the risk of bleeding, but the data of the result did not reach the statistical significance (OR 1.44, 95% CI 0.69-3.00, P = 0.32).
  
  
  CONCLUSIONS
  Tirofiban is more effective than conventional drugs for NR during PCI, but the potential risk of bleeding complication induced by tirofiban shouldn't be ignored during clinical practices.
authors.affiliation: Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi, Medical University, Nanning, Guangxi, 530027, P, R, China. cmhnn@sina.com.
authors.forename: Tao
authors.initials: T
authors.lastname: Qin
authors.forename: Lu
authors.initials: L
authors.lastname: Xie
authors.forename: Meng-Hua
authors.initials: MH
authors.lastname: Chen
mesh_terms: D003331:Coronary Vessels / Q000187:drug effects*; D006801:Humans; D007269:Injections, Intra-Arterial; D054318:No-Reflow Phenomenon / Q000188:drug therapy*; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic / Q000009:adverse effects / Q000379:methods; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D000077466:Tirofiban
references.citation: Am J Cardiol. 2005 Jan 1;95(1):20-3
references.pmid: 15619388
references.citation: Cardiovasc Drugs Ther. 2000 Dec;14(6):651-5
references.pmid: 11300366
references.citation: Int J Cardiol. 2011 Dec 15;153(3):249-55
references.pmid: 20971515
references.citation: Cathet Cardiovasc Diagn. 1996 Oct;39(2):113-8
references.pmid: 8922307
references.citation: J Am Coll Cardiol. 1998 Jan;31(1):23-30
references.pmid: 9426013
references.citation: J Am Coll Cardiol. 2000 Oct;36(4):1202-9
references.pmid: 11028471
references.citation: Catheter Cardiovasc Interv. 2008 Dec 1;72(7):950-7
references.pmid: 19021281
references.citation: BMC Med. 2010 Jun 16;8:36
references.pmid: 20553581
references.citation: Circulation. 2003 Apr 29;107(16):2115-9
references.pmid: 12695301
references.citation: Exp Clin Cardiol. 2008 Fall;13(3):121-8
references.pmid: 19343126
references.citation: Lancet. 1999 Jan 16;353(9148):227-31
references.pmid: 9923894
references.citation: Am Heart J. 2012 Sep;164(3):394-401
references.pmid: 22980307
references.citation: Circulation. 1994 Jun;89(6):2514-8
references.pmid: 8205658
references.citation: Am J Cardiol. 2007 Feb 15;99(4):442-5
references.pmid: 17293180
references.citation: J Interv Cardiol. 2005 Aug;18(4):261-6
references.pmid: 16115155
references.citation: Circulation. 2005 Mar 8;111(9):1160-5
references.pmid: 15723983
references.citation: Circ Cardiovasc Interv. 2010 Feb 1;3(1):27-33
references.pmid: 20118156
references.citation: Circulation. 1998 Jun 16;97(23):2302-6
references.pmid: 9639373
references.citation: J Am Coll Cardiol. 2009 Jul 21;54(4):281-92
references.pmid: 19608025
references.citation: J Am Coll Cardiol. 2001 Sep;38(3):666-71
references.pmid: 11527614
references.citation: J Am Coll Cardiol. 2002 Feb 20;39(4):591-7
references.pmid: 11849856
references.citation: Am Heart J. 2003 Jan;145(1):42-6
references.pmid: 12514653
references.citation: Cardiovasc Revasc Med. 2008 Jan-Mar;9(1):56-61
references.pmid: 18206640
references.citation: Thromb Res. 2005;116(1):55-66
references.pmid: 15850609
references.citation: Semin Intervent Radiol. 2010 Dec;27(4):412-21
references.pmid: 22550383
references.citation: J Invasive Cardiol. 2002 Jun;14(6):299-302
references.pmid: 12042618
references.citation: Arch Inst Cardiol Mex. 1998 May-Jun;68(3):247-52
references.pmid: 9810347
references.citation: Chin Med J (Engl). 2009 Nov 20;122(22):2718-23
references.pmid: 19951602
references.citation: Jpn Circ J. 1995 Dec;59(12):790-8
references.pmid: 8788370